Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.
about
Current and future regenerative medicine - principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicineA comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transferHigh systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis?Animal Models of Osteoarthritis: Comparisons and Key ConsiderationsDevelopment of an equine groove model to induce metacarpophalangeal osteoarthritis: a pilot study on 6 horsesPost-traumatic arthritis: overview on pathogenic mechanisms and role of inflammationOptimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.Immunopathogenesis of osteoarthritisOrthopedic gene therapy in 2008.Revisiting the Role of Interleukin-1 Pathway in Osteoarthritis: Interleukin-1α and -1β, and NLRP3 Inflammasome Are Not Involved in the Pathological Features of the Murine Menisectomy Model of Osteoarthritis.Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.Lubricin/proteoglycan 4 increases in both experimental and naturally occurring equine osteoarthritis.Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection.Treatment of experimentally induced osteoarthritis in horses using an intravenous combination of sodium pentosan polysulfate, N-acetyl glucosamine, and sodium hyaluronan.Temporal expression and tissue distribution of interleukin-1β in two strains of guinea pigs with varying propensity for spontaneous knee osteoarthritis.Key Pathways to Prevent Posttraumatic Arthritis for Future Molecule-Based Therapy.Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.Gene therapy for arthritis.Perspectives on the use of gene therapy for chronic joint diseases.A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.Gene-based approaches for the repair of articular cartilage.Osteoarthritis gene therapy.Effect of self-assembling peptide, chondrogenic factors, and bone marrow-derived stromal cells on osteochondral repairSelf-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins.Inflammation in joint injury and post-traumatic osteoarthritisLarge animal models and gene therapy.Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat modelscAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints.RNA Interference Mediated Interleukin-1β Silencing in Inflamed Chondrocytes Decreases Target and Downstream Catabolic Responses.Non-terminal animal model of post-traumatic osteoarthritis induced by acute joint injury.The horse as a model of naturally occurring osteoarthritis.Persistence, localization, and external control of transgene expression after single injection of adeno-associated virus into injured joints.Novel approaches for treating musculoskeletal diseases: molecular orthopedics and systems medicine.Use of autologous conditioned serum (Orthokine) for the treatment of the degenerative osteoarthritis of the temporomandibular joint. Review of the literatureGene therapy for articular cartilage repair.Adeno-associated viral vectors show serotype specific transduction of equine joint tissue explants and cultured monolayersConcepts in gene therapy for cartilage repair.Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental studyGene therapy of the rheumatic diseases: 1998 to 2008.Dynamic compression stimulates proteoglycan synthesis by mesenchymal stem cells in the absence of chondrogenic cytokines.
P2860
Q24646497-FFBE0CDA-5ABF-4C5C-9D0B-B48B7E3E895EQ24797774-358DCE2C-BC3A-4051-A5D0-3165A40377C3Q26800733-46E80C21-B25E-49AB-BC7E-6ECD14B65F8BQ26998936-7A70CE81-ED68-4365-BFE4-AB432A62D1F8Q27320572-BC6C4F25-5712-420B-9213-B60A9482A48DQ28067614-DC2D4D12-B3F3-43CA-B6F9-ACFFB9375408Q30537079-E614F194-EE80-45AA-B33E-D1E83AA12BE2Q33587966-07B95DAF-582A-4D80-B91C-22886CB4E69BQ33713231-23E3F8CE-EC03-4751-B32B-0DBD8763529AQ33790090-CDEFA154-9831-4B97-A48B-7A7E46338CC4Q33791993-D41D79C9-C54B-47B0-8514-41A07F963234Q33847985-4255EA45-1311-4099-9C89-E43000AA6023Q34027603-FA948950-9C5C-4A48-BA89-C1D1A06D86EEQ34419665-6155A545-645C-4F6F-AF8B-3096D475295CQ34778033-1AA7FC8C-1835-4AC0-898A-87B0CE2E629CQ34977905-02ABE708-993E-480E-A63C-D522BD93C9C0Q35064664-AE75012C-0165-4BD6-A1C8-100F284C6DAFQ35122176-CDE97486-A7CC-4715-995C-93AF4EFF09C0Q35151031-FCDD1EB6-15CF-4F6B-9DB3-A45325DE44B4Q35617678-E024E8BD-9090-44F5-B245-B63B6670294AQ35629558-F0753A50-78E9-43BC-9276-C005C0C4D151Q35629588-521E5930-10DA-41C8-870A-7CC6F712203CQ35669263-0F4C7ABD-8293-4DDA-B8E6-AC3E3BC9A4DDQ36162174-C3157A33-7BE4-4DD2-A06C-F809ACBC5A88Q36242292-DC9A3941-42B5-4133-BC23-51D4D6D649E7Q36333340-E2446503-5F47-4015-A2D3-FA79AC0F8DFBQ36466909-A00EE65B-D57E-42A1-86A9-F81A48350E3BQ36625357-22CEF777-842E-4275-BA40-C8BCA528A946Q36747491-DB6E2AF5-4419-4930-A2A0-D4D45923B9B2Q36759459-1CFAF9E1-A249-46EF-BB99-D066F6EAE9E6Q36765477-E95E8891-CE2A-48C1-84A5-E5B90A3AF8CCQ36780068-5CAF43BD-F8C3-464A-BF67-E6D0C321E5DCQ36876937-8253B25F-4372-4C76-8CFB-9AF84FC12C46Q36891196-64D4209D-016B-4F1D-B485-F5E319CBA304Q36932626-76F8C5C7-1CFF-48F9-9DD1-6755EB6558F2Q36972596-8495D07A-6E48-44A1-848B-4F79D7D99336Q37099568-093B728A-5340-492A-9717-2BF5E3F70A17Q37206899-82E4C104-1B73-40F3-9EEA-376CBA5A6313Q37207021-FE248D8C-8EE5-4918-A58D-BEB29E282BB2Q37471357-64368FBD-8637-462A-A97B-EA6E5DDD134A
P2860
Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Treatment of experimental equi ...... in-1 receptor antagonist gene.
@en
type
label
Treatment of experimental equi ...... in-1 receptor antagonist gene.
@en
prefLabel
Treatment of experimental equi ...... in-1 receptor antagonist gene.
@en
P2093
P2860
P356
P1433
P1476
Treatment of experimental equi ...... in-1 receptor antagonist gene.
@en
P2093
Frisbie DD
Ghivizzani SC
McIlwraith CW
Robbins PD
P2860
P2888
P356
10.1038/SJ.GT.3301608
P577
2002-01-01T00:00:00Z
P6179
1041387729